Tobacco smoking is the leading cause of preventable disease and death in the United States, resulting in approximately 480,000 premature deaths and more than $300 billion in direct health care expenditures and productivity losses each year (1) . To assess progress toward achieving the Healthy People 2020 objective of reducing the percentage of U.S. adults who smoke cigarettes to ≤12.0%,* CDC assessed the most recent national estimates of smoking prevalence among adults aged ≥18 years using data from the 2014 National Health Interview Survey (NHIS). The percentage of U.S. adults who smoke cigarettes declined from 20.9% in 2005 to 16.8% in 2014. Among daily cigarette smokers, declines were observed in the percentage who smoked 20-29 cigarettes per day (from 34.9% to 27.4%) or ≥30 cigarettes per day (from 12.7% to 6.9%). In 2014, prevalence of cigarette smoking was higher among males, adults aged 25-44 years, multiracial persons and American Indian/Alaska Natives, persons who have a General Education Development certificate, live below the federal poverty level, live in the Midwest, are insured through Medicaid or are uninsured, have a disability or limitation, or are lesbian, gay, or bisexual. Proven population-based interventions, including tobacco price increases, comprehensive smoke-free laws, high impact mass media campaigns, and barrier-free access to quitting assistance, are critical to reduce cigarette smoking and smoking-related disease and death among U.S. adults. † NHIS is an annual, nationally representative, in-person survey of the noninstitutionalized U.S. civilian population. The NHIS core questionnaire is administered to a randomly selected adult in each sampled family. The 2014 NHIS included 36,697 respondents aged ≥18 years; the response rate was 58.9%. Current cigarette smokers were respondents who reported smoking ≥100 cigarettes during their lifetimes and, at the time of interview, reported smoking every day or some days. Former cigarette smokers were respondents who reported smoking ≥100 cigarettes during their lifetime but currently did not smoke.
Data were adjusted for differences in the probability of selection and nonresponse, and weighted to provide nationally representative estimates. Current smoking was assessed overall and by sex, age, race/ethnicity, education, poverty status, § U.S. Census region, ¶ What is added by this report?
Cigarette smoking among U.S. adults declined from 20.9% in 2005 (45.1 million smokers) to 16.8% in 2014 (40.0 million); cigarette smoking declined a full percentage point from 2013 to 2014 alone. However, disparities in smoking prevalence persist. In 2014, cigarette smoking prevalence was higher among adults on Medicaid (29.1%) and uninsured adults (27.9%) than among adults with private health insurance (12.9%).
What are the implications for public health practice?
Proven population-based interventions, including tobacco price increases, comprehensive smoke-free laws, high-impact tobacco education mass media campaigns, and barrier-free access to quitting assistance, are critical to reduce cigarette smoking and smoking-related disease and death among U.S. adults.. ** Medicaid only: Anyone reporting having Medicaid coverage, but no other insurance coverage, at the time of the interview. Persons reporting both Medicaid and "private insurance" were included in the "private insurance" category. Medicare only: Anyone reporting having Medicare coverage, but no other insurance coverage, at the time of the interview. Persons reporting both Medicare and "private insurance" were included in the "private insurance" category. Private insurance: Any comprehensive private insurance plan (including health maintenance and preferred provider organizations), obtained through an employer, purchased directly, or purchased through local or community programs, and excludes plans that pay for only one type of service, such as accidents or dental care. A small number of persons (132 respondents) were covered by both "other public insurance" and private plans and were included in both categories. For 2014, this group also included plans purchased through the Health Insurance Marketplace or a state-based exchange. Other public insurance: Includes Children's Health Insurance Program, statesponsored or other government-sponsored health plan, and military plans. A small number of persons (132 respondents) were covered by both "other public insurance" and private plans and were included in both categories. This does not include anyone reporting any Medicare or Medicaid coverage. Uninsured: Having no private health insurance, Medicare, Medicaid, Children's Health Insurance Program, state-sponsored or other government-sponsored health plan, or military plan, or having only Indian Health Service coverage, or having only a private plan that paid for one type of service, such as accidents or dental care. Those who were dual eligible (enrolled in both Medicaid and Medicare) or reported Medicaid or Medicare and any other coverage were excluded unless they also had "private" insurance coverage. † † Based on self-reported presence of selected impairments including vision, hearing, cognition, and movement. Limitations in performing activities of daily living defined based on response to the question, "Because of a physical, mental, or emotional problem, does [person] need the help of other persons with personal care needs, such as eating, bathing, dressing, or getting around inside this home?" Limitations in performing instrumental activities of daily living defined based on response to the question, "Because of a physical, mental, or emotional problem, does [person] need the help of other persons in handling routine needs, such as everyday household chores, doing necessary business, shopping, or getting around for other purposes?" Any disability/ limitation was defined as a "yes" response pertaining to at least one of the disabilities/limitations listed (i.e., vision, hearing, cognition, movement, activities of daily living, or instrumental activities of daily living). In 2014, the American Community Survey questions were asked of a random half of the respondents from the 2014 Person File. For population estimates, the specific adult disability weight was doubled to account for the half of respondents who were not asked these questions. § § Starting in 2013, sexual orientation questions were added to NHIS. To determine sexual orientation, adult respondents were asked, "Which of the following best represents how you think of yourself?" with response options of gay ("lesbian or gay" for female respondents), straight, that is, "not gay" ("not lesbian or gay" for female respondents), bisexual, something else, and I don't know the answer. (Figure 3 ) (p<0.05 for trend).
Discussion
During 2005-2014, the prevalence of cigarette smoking among U.S. adults declined from 20.9% to 16.8%, including by a full percentage point during 2013-2014 alone, indicating marked progress toward achieving the Healthy People 2020 goal of reducing cigarette smoking prevalence to ≤12.0%. Adults aged 18-24 years experienced the greatest decrease in cigarette smoking prevalence; however, recent reports suggest that use of noncigarette tobacco products, including e-cigarettes and hookahs, is common among youth and young adults (2, 3) . The extent to which emerging tobacco products, such as e-cigarettes, might have contributed to the observed decline in cigarette smoking in recent years is uncertain. E-cigarette use was first assessed in NHIS in 2014, so it is not possible to assess long term patterns of e-cigarette use relative to cigarette use with this dataset; in 2014, 3.7% of adults currently used e-cigarettes every day or some days, with use differing by age, race/ethnicity, and cigarette smoking status (4). E-cigarettes have been promoted for smoking cessation (1); however, the U.S. Preventive Services Task Force has concluded that the current evidence is insufficient to recommend e-cigarettes for tobacco cessation in adults, including pregnant women. ¶ ¶ No change occurred in the percentage of former cigarette smokers over time, suggesting that some of the decline in cigarette smoking might be driven by overall reductions in smoking initiation.
Observed disparities in smoking prevalence are consistent with previous studies (5) . Differences by race/ethnicity might be partly explained by sociocultural influences and norms related to the acceptability of tobacco use (6) . Differences in prevalence among persons with different types of health insurance coverage might be partly attributable to variations in tobacco cessation treatment coverage and access to evidencebased cessation treatments across health insurance types (7).
Higher prevalences among persons with disabilities and limitations might be related, in part, to smoking-attributable disability in smokers and possible higher stress associated with disabilities (8) . These disparities underscore the importance of enhanced implementation of proven strategies to prevent and reduce tobacco use.
Ongoing changes in the U.S. health care system offer opportunities to improve the use of clinical preventive services among adults. The Patient Protection and Affordable Care Act of 2010 (ACA) is increasing the number of Americans with health insurance and is expected to improve tobacco cessation coverage (7) . The ACA requires most private insurers to cover tobacco cessation (7); a guidance document issued in May 2014 further clarified this ACA provision.*** However, neither private insurers nor state Medicaid programs consistently provide comprehensive coverage of evidence-based cessation treatments (7, 9) . In 2015, although all 50 state Medicaid programs covered some tobacco cessation treatments for some Medicaid enrollees, only nine states covered individual ¶ ¶ Additional information available at http://www.uspreventiveservicestaskforce. o r g / P a g e / D o c u m e n t / R e c o m m e n d a t i o n S t a t e m e n t F i n a l / tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions1. *** Additional information available at http://www.dol.gov/ebsa/faqs/faq-aca19.html. and group counseling and all seven FDA-approved cessation medications for all Medicaid enrollees (9) . Cessation coverage has the greatest impact when promoted to smokers and health care providers (7, 9) . The findings in this report are subject to at least five limitations. First, smoking status was self-reported and not validated by biochemical testing; however, self-reported smoking status correlates highly with serum cotinine levels (10) . Second, because NHIS does not include institutionalized populations and persons in the military, results are not generalizable to these groups. Third, the NHIS response rate of 58.9% might have resulted in nonresponse bias. Fourth, the questionnaire did not assess gender identity; including transgender persons might yield higher smoking estimates among sexual minorities. Finally, these estimates might differ from other surveys on tobacco use. These differences in estimates can be partially explained by varying survey methodologies, types of surveys administered, and definitions of current smoking; however, trends in prevalence are comparable across surveys.
Sustained comprehensive state tobacco control programs funded at CDC-recommended levels could accelerate progress toward reducing the health and economic burden of tobaccorelated diseases in the United States (1). However, during 2015, states will spend only $490.4 million (1.9%) of combined revenues of $25.6 billion from settlement payments and tobacco taxes for all states on comprehensive tobacco control programs, † † † representing <15% of the CDC-recommended level of funding for all states combined. Moreover, only two states (Alaska and North Dakota) currently fund tobacco control programs at CDC-recommended levels. Implementation of comprehensive tobacco control interventions can result in substantial reductions in tobacco-related morbidity and mortality and billions of dollars in savings from averted medical costs (1). Additionally, states can work with health care systems, insurers, and purchasers of health insurance to improve coverage and utilization of tobacco cessation treatments and to implement health systems changes that make tobacco dependence treatment a standard of clinical care (7, 9 Congenital syphilis (CS) occurs when a mother infected with syphilis transmits the infection to her child during pregnancy. CS can cause severe illness, miscarriage, stillbirth, and early infant death. However, among pregnant women with syphilis who deliver after 20 weeks gestation, maternal treatment with penicillin is 98% effective at preventing CS (1) CS is a nationally notifiable disease with case data reported to CDC by all 50 states and the District of Columbia through the National Notifiable Diseases Surveillance System.* For surveillance purposes, the definition of a CS case includes both stillbirths and infants with clinical evidence of CS, as well as stillbirths and infants born to mothers with untreated or inadequately treated syphilis, regardless of the infant's manifestation of clinical disease. CDC analyzed cases of CS reported during 2008-2014, describing selected demographic and clinical features of infants with CS and their mothers. CS rates were calculated as cases per 100,000 live births by using U.S. natality data published by the National Center for Health Statistics (4). Rates of primary and secondary (P&S) syphilis, a measure that combines two stages of recently acquired infectious syphilis to monitor incident disease, were calculated among women as cases per 100,000 women by using U.S. Census population estimates (5) . Because 2014 natality and Census data were not yet available, CS and P&S rates for 2014 were calculated by using 2013 denominators.
Disease Trends
The number of CS cases declined in the United States during 2008-2012 from 446 to 334 cases (10.5 to 8.4 cases per 100,000 live births), reflecting trends in rates of P&S syphilis among women, which decreased from 1.5 to 0.9 cases per 100,000 women ( Figure) . During this period, all regions of the United States experienced a decrease in CS rates except the Midwest, where the rate increased 62% (from 4.2 to 6.8 cases per 100,000 live births) ( Table 1 ). † The increase in CS in the Midwest was attributed primarily to increases in CS rates in Illinois and Ohio, which occurred 1-2 years after observed increases in P&S syphilis among women in these states (6) . Substantial declines occurred in all other regions (51% in the Northeast, 46% in the West, and 16% in the South), leading to an overall national decline in CS rates to the lowest level since 2005.
Racial disparities in CS rates between non-Hispanic blacks (blacks) and non-Hispanic whites (whites) increased during 2008-2012, because relative decreases in rates of CS were greater among whites (21%) than blacks (11%). As has been observed previously, the majority of CS cases (57%) in 2012 continued to be among infants whose mothers were black (2).
During 2012-2014, the number of reported CS cases in the United States increased from 334 to 458, representing an increase in rate from 8.4 to 11.6 cases per 100,000 live births. As has been observed with earlier CS trends (2), the increase in CS rates during 2012-2014 reflected an increase in the rate of P&S syphilis among women (22.2% increase, from 0.9 to 1.1 cases per 100,000 women) during the same period ( Figure) . Increases in CS rates occurred in all regions but were greatest in the West, where the rate more than doubled (from 5.5 to 12.8 cases per 100,000 live births) ( 
Increase in Incidence of

Clinical Characteristics
The proportion of CS cases resulting in stillbirth and early infant death increased slightly during 2008-2014 (Table 2) Among 428 CS patients born alive in 2014, 28 (6.5%) had one or more clinical sign or symptom of CS infection ( Table 3 ). The most commonly reported signs were syphilitic rash (n = 8), jaundice (n = 8), and hepatosplenomegaly (n = 5). An additional 49 (11.4%) had other evidence of CS infection, including long bone x-ray findings consistent with CS, a reactive cerebrospinal fluid (CSF) venereal disease research laboratory test, or an elevated CSF white blood cell count or protein level in the absence of another etiology. Forty-two infants (9.8%) did not have treatment recorded at the time the case was reported to CDC. § Among 458 mothers of infants with CS in 2014, 100 (21.8%) received no prenatal care, and no information about prenatal care was available for 44 mothers (9.6%) ( Table 3) . Among the 314 mothers with one or more prenatal visit, 135 (43.0%) received no treatment for syphilis during the course of their pregnancy and 94 (30.0%) received inadequate treatment. The 135 mothers who received no treatment include 21 mothers who were never tested for syphilis during pregnancy and 52 mothers who tested negative for syphilis in early pregnancy and subsequently acquired syphilis before delivery. The remaining 62 mothers tested positive, but were not treated. Benzathine penicillin G is the only known effective treatment for preventing CS (3). Maternal treatment was considered inadequate if it was initiated too late (<30 days before delivery), if a nonpenicillin therapy was administered, or if the dose of penicillin administered was inadequate for the mother's stage of syphilis.
Discussion
The rate of CS in the United States reached a low of 8.4 cases per 100,000 live births in 2012, after 4 years of steady decline. However, during 2012-2014, the national CS rate increased 38%. This rapid increase in the CS rate coincided with a 22% national increase in the rate of P&S syphilis among women during the same period.
In the United States, a case of CS is a sentinel event reflecting numerous missed opportunities for prevention within public health and health care systems (7). There are two major opportunities to prevent CS: primary prevention of syphilis among women of reproductive age and men who have sex with women, and prevention of mother-to-infant transmission among pregnant women already infected with syphilis.
Preventing syphilis among women and their male partners requires that sexually transmitted diseases (STD) prevention programs quickly identify and respond to increases in syphilis cases among women and men who have sex with women in their jurisdictions. CS cases and cases of syphilis among women should be reported to the local health department within 24 hours of diagnosis, and STD programs should review local syphilis case data each week to detect increases in CS cases or cases of syphilis among women. In addition, CS cases should be reported to CDC within 1 month of diagnosis. STD programs should prioritize cases of infectious syphilis among women of reproductive age and their male sex partners for case investigation and partner services to reduce transmission and infection in these populations. STD programs might also consider enhancing surveillance efforts by determining pregnancy status on all reported syphilis cases in women and by monitoring the screening and treatment practices among prenatal care providers in communities at highest risk for delivering an infant with CS.
Mother-to-infant transmission of syphilis can be prevented or mother-to-infant transmission that has already occurred can § Newborn treatment for congenital syphilis might include either a 10-day course of aqueous crystalline or procaine penicillin G or one intramuscular dose of benzathine penicillin G, depending upon various factors related to 1) identification of syphilis in the mother; 2) adequacy of maternal treatment; 3) presence of clinical, laboratory, or radiographic evidence of syphilis in the neonate; and 4) comparison of maternal (at delivery) and neonatal serologic titers. Full guidance is available at http://www.cdc.gov/std/tg2015/congenital.htm. be treated when maternal syphilis is detected, and benzathine penicillin G appropriate for the mother's stage of infection ¶ is initiated ≥30 days before delivery (3) . CDC recommends that all pregnant women be screened for syphilis at their first prenatal visit (3). Women at increased risk for syphilis and women living in high-morbidity geographic areas should also be screened at the beginning of their third trimester and again at delivery.** When access to prenatal care is not optimal, rapid plasma reagin screening should be performed at the time that a pregnancy is confirmed (performed onsite by using a rapid plasma reagin card test, if possible, and the woman treated as necessary). Newborn infants should not be discharged from the hospital unless the syphilis serologic status of the mother has been determined at least one time during pregnancy and preferably again at delivery if the mother is determined to be at increased risk. Any woman who delivers a stillborn infant should be tested for syphilis. A substantial percentage of CS cases are attributable to a lack of prenatal care; even among those receiving some prenatal care, the detection and treatment of maternal syphilis often occurs too late to prevent CS. Health departments, in partnership with prenatal care providers and other local organizations, should work together to address barriers to obtaining early and adequate prenatal care for the majority of vulnerable pregnant women. Women who are uninsured or underinsured and women with substance use issues have been found to be at increased risk for receiving inadequate or no prenatal care, placing them at increased risk for CS (8, 9) .
The findings in this report are subject to at least three limitations. First, shortcomings in screening practices (e.g., inconsistent syphilis testing of mothers with stillborn infants) or underreporting can lead to missed cases (10) . Second, this analysis only stratified data at the regional and state levels; the observations reported here might not reflect more local (e.g., county-or city-level) epidemiology. Third, the use of 2013 natality data in the calculation of CS rates might overestimate the rate of CS by a limited amount; preliminary data indicate that births might have increased slightly in the United States during 2013-2014. What is added by this report?
Although the rate of CS steadily decreased during 2008-2012 (10.5 cases to 8.4 cases per 100,000 live births), the rate increased during 2012-2014 (11.6 cases per 100,000 live births in 2014), reflecting an increase in the national rate of primary and secondary syphilis among women. The 2014 CS rate is higher than seen in over a decade.
CS and its complications can be prevented by rapidly responding to syphilis increases among women of reproductive age and men who have sex with women, and by quality prenatal care, which includes screening and treatment for syphilis. Although the United States experienced an overall decline in the rate of CS during 2008-2012, the rate increased substantially during 2012-2014, to the highest level since 2001. Racial and ethnic disparities persist, and CS prevention in the public health and health care sectors remains paramount. Addressing CS will depend upon health care providers and STD programs being aware of infectious syphilis among women of reproductive age and men who have sex with women in their jurisdictions; reporting cases of CS and cases of syphilis among women of reproductive age and men who have sex with women in a timely fashion; prioritizing STD partner services for syphilis cases among women of reproductive age and their sex partners; instituting more thorough prenatal screening practices when warranted; ensuring timely treatment of identified cases with benzathine penicillin G; and removing the barriers to timely and high quality prenatal care.
In 2000, the United Nations General Assembly adopted the Millennium Development Goals (MDG), with MDG4 being a two-thirds reduction in child mortality by 2015, and with measles vaccination coverage being one of the three indicators of progress toward this goal.* In 2010, the World Health Assembly established three milestones for measles control by 2015: 1) increase routine coverage with the first dose of measles-containing vaccine (MCV1) for children aged 1 year to ≥90% nationally and ≥80% in every district; 2) reduce global annual measles incidence to fewer than five cases per million population; and 3) reduce global measles mortality by 95% from the 2000 estimate (1). † In 2012, the World Health Assembly endorsed the Global Vaccine Action Plan § with the objective to eliminate measles in four World Health Organization (WHO) regions by 2015. WHO member states in all six WHO regions have adopted measles elimination goals. This report updates the 2000-2013 report (2) and describes progress toward global control and regional measles elimination during 2000-2014. During this period, annual reported measles incidence declined 73% worldwide, from 146 to 40 cases per million population, and annual estimated measles deaths declined 79%, from 546,800 to 114,900. However, progress toward the 2015 milestones and elimination goals has slowed markedly since 2010. To resume progress toward milestones and goals for measles elimination, a review of current strategies and challenges to improving program performance is needed, and countries and their partners need to raise the visibility of measles elimination, address barriers to measles vaccination, and make substantial and sustained additional investments in strengthening health systems.
Immunization Activities
To estimate coverage with MCV1 and the second dose of MCV (MCV2) through routine immunization services, ¶ WHO and the United Nations Children's Fund (UNICEF) use data from administrative records and surveys reported annually by the 194 WHO countries. From 2000 to 2010, estimated MCV1 coverage increased globally from 72% to 85%, and remained at 85% through 2014 (Tables 1 and 2 Jean-Marie Okwo-Bele, MD 1 ; Paul A. Rota, PhD 2 ; James L. Goodson, MPH 3 ¶ For MCV1, among children aged 1 year or, if MCV1 is given at age ≥1 year, among children aged 24 months. For MCV2, among children at the recommended age of administration of MCV2, as per the national immunization schedule. WHO/UNICEF estimates of national immunization coverage are available at http://www.who.int/immunization/monitoring_ surveillance/data. ** Supplemental immunization activities (SIAs) generally are carried out using two target age ranges. An initial, nationwide catch-up SIA focuses on all children aged 9 months-14 years, with the goal of eliminating susceptibility to measles in the general population. Periodic follow-up SIAs then focus on all children born since the last SIA. Follow-up SIAs generally are conducted nationwide every 2-4 years and focus on children aged 9-59 months; their goal is to eliminate any measles susceptibility that has developed in recent birth cohorts and to protect children who did not respond to MCV1.
* Additional information available at http://www.unmillenniumproject.org/goals/ gti.htm#goal4. † Whereas the coverage milestone is to be met by every country, the incidence and mortality reduction milestones are to be met globally. § The Global Vaccine Action Plan is the implementation plan of the Decade of Vaccines, a collaboration between WHO, UNICEF, the Bill and Melinda Gates Foundation, Gavi, the Vaccine Alliance, the U.S. National Institute of Allergy and Infectious Diseases, the African Leaders Malaria Alliance, and others to extend the full benefit of immunization to all persons by 2020 and beyond. Additional information is available at http://www.who.int/immunization/ global_vaccine_action_plan and at http://apps.who.int/gb/ebwha/pdf_files/ wha65/a65_22-en.pdf. Abbreviations: SIA = supplementary immunization activity; WHO = World Health Organization. * SIAs typically are carried out using two approaches: 1) An initial, nationwide catch-up SIA targets all children aged 9 months-14 years, with the goal of eliminating susceptibility to measles in the general population and periodic follow-up SIAs then target all children born since the last SIA. 2) Follow-up SIAs are typically conducted nationwide every 2-4 years and typically target children aged 9-59 months; their goal is to eliminate any measles susceptibility that has developed in recent birth cohorts and to protect children who did not respond to the first measles vaccination. The exact age range for follow-up SIAs depends on the age-specific incidence of measles, coverage with 1 dose of measles-containing vaccine, and the time since the last SIA. † When coverage >100% the intervention reached more persons than the estimated target population. § Rollover national campaigns started the previous year or will continue into the next year.
however, of the five countries conducting post-SIA coverage surveys, only one estimated SIA coverage at ≥95%.
Disease Incidence
Countries report the number of measles cases from either case-based or aggregate surveillance systems † † to WHO and UNICEF each year. Effective measles surveillance includes casebased surveillance with laboratory testing to confirm cases. In 2014, 187 (96%) § § countries used case-based surveillance, and 191 (98%) ¶ ¶ had access to standardized quality-controlled testing through the WHO Global Measles and Rubella Laboratory Network.
During 2000-2014, the number of annually reported measles cases worldwide decreased 69%, from 853,479 to 267,482, and measles incidence decreased 73%, from 146 to 40 cases per million population (Tables 1 and 2 Measles incidence decreased in four of six WHO regions from 2013 to 2014 (Table 2 ). In the African Region (AFR), reported cases decreased 57%, from 171,178 cases in 2013 to 73,914 in 2014, largely because of decreases in the Democratic Republic of the Congo (from 88,381 to 33,711) and Nigeria (from 52,852 to 6,855). However, in 2014, outbreaks occurred in Angola (11,699) and Ethiopia (12,739 cases). In the Eastern Mediterranean Region (EMR), the European Region (EUR), and the South-East Asia Region (SEAR), reported cases also decreased in 2014, although large outbreaks were reported in India (24,977), Somalia (10,278 cases), and Russia (4,711) in 2014. Increased numbers of cases were reported in 2014 from AMR, largely because of outbreaks in Brazil (727 cases) and the United States (667); and from the Western Pacific Region (WPR), because of large outbreaks reported in China (52,628), the Philippines (58,848 cases), and Vietnam (15,033).
Genotypes of viruses isolated from measles cases were reported to WHO by 69 (41%) of the 169 countries reporting measles cases in 2014. Of the 24 recognized measles virus genotypes, 11 were detected during 2005-2008 and eight during 2009-2014, excluding those from vaccine reactions and cases of subacute sclerosing panencephalitis (3). In 2014, among 7,155 reported sequences, † † † 1,328 (50 countries) were genotype B3, 38 (eight countries) were D4, 1,083 (45 countries) were D8, 92 (12 countries) were D9, four (four countries) were G3, and 4,610 (18 countries) were H1 ( Table 2) .
Mortality Estimates
WHO has developed a model to estimate measles mortality in countries using numbers and age distribution of reported cases, routine and SIA MCV coverage, and age-and countryspecific case-fatality ratios (4, 5) . New measles vaccination coverage and case data for all countries during 2000-2014 † † Available at http://apps.who.int/immunization_monitoring/globalsummary/ timeseries/tsincidencemeasles.html. § § Countries without case-based measles surveillance in 2014 were Djibouti, India, Mauritius, Sao Tome and Principe, Seychelles, Somalia, and South Sudan. led to a new series of mortality estimates. During this period, estimated measles deaths decreased 79%, from 546,800 to 114,900, and all regions had substantial reductions in estimated measles mortality (Tables 1 and 2 
Regional Verification of Measles Elimination
Since the last report, the AMR regional verification committee determined that AMR cannot be declared measles free, because Brazil has had sustained transmission of a single measles virus strain for >1 year. The WPR regional verification committee verified absence of endemic measles in two member states and one area, bringing the total to seven in WPR (6); the EUR regional verification committee verified measles elimination in 22 member states (7).
Discussion
During 2000-2014, increased coverage worldwide with both (1st and 2nd) routine doses of MCV, combined with SIAs in countries that lack high coverage with 2 doses of MCV, contributed to a 73% decrease in reported measles incidence and a 79% reduction in estimated measles mortality. During this period, measles vaccination prevented an estimated 17.1 million deaths. However, on the basis of current trends in measles vaccination coverage and incidence, the WHO Strategic Advisory Group of Experts on Immunization concluded that the 2015 global milestones and measles elimination goals will not be achieved (8) .
Measles can serve as an indicator of the strength and reach of the health system, as measles outbreaks reveal populations poorly served by health services. In high-burden, low-coverage countries, outbreak investigations have also found low MCV1 coverage where long-standing policies and practices prevent vaccination of children aged ≥12 months, discourage opening a 10-dose vial when few children are present, and limit measles vaccination to only one session per month (Global Immunization Division, Center for Global Health, CDC, unpublished data, 2015). Addressing these gaps, maximizing how SIA planning and implementation can improve routine services, and conducting high-quality SIAs should increase coverage and equity for all vaccines and further reduce the number of measles cases and deaths. As coverage improves, establishing a visit during the second year of life integrating MCV2 and other child health interventions should help to further reduce measles burden.
The findings in this report are subject to at least three limitations. First, MCV coverage estimates are affected by inclusion of SIA doses administered to children outside the target group, inaccurate estimates of the target population size, and inaccurate reports of the number of doses delivered. Second, underascertainment of measles cases through surveillance systems can occur, because not all patients with measles seek care and not all cases are reported. Third, some countries report aggregate numbers of unconfirmed cases rather than case-based data.
The decrease in measles mortality is among three main contributors (along with decreases in pneumonia and diarrhea) to the decline in overall child mortality and progress toward MDG4 (9) . To assess the reasons for the slowing of progress since 2010 and to modify current strategies as needed, the Measles & Rubella Initiative § § § partners have commissioned a midterm strategy review. Countries and their partners need to raise the visibility of measles elimination, and secure the resources needed to implement strategies required to reach measles control and elimination goals, taking into account the results and recommendations from the review. What are the implications for public health practice?
Although measles vaccination has saved millions of lives since 2000, progress has slowed since 2010. Reaching measles control and elimination goals will require addressing policy and practice gaps that prevent reaching larger numbers of children with measles vaccination, increasing visibility of measles elimination efforts, and ensuring adequate resources for strengthening health systems.
The year 2014 marked the 40th anniversary of the World Health Organization's (WHO) Expanded Program on Immunization, which was established to ensure equitable access to routine immunization services (1) . Since 1974, global coverage with the four core vaccines (Bacille CalmetteGuérin vaccine [BCG; for protection against tuberculosis], diphtheria-tetanus-pertussis [DTP] vaccine, poliovirus vaccine, and measles vaccine) has increased from <5% to ≥85%, and additional vaccines have been added to the recommended schedule. Coverage with the 3rd dose of DTP vaccine (DTP3) by age 12 months is an indicator of immunization program performance because it reflects completion of the basic infant immunization schedule; coverage with other vaccines, including the 3rd dose of poliovirus vaccine (polio3); the 1st dose of measles-containing vaccine (MCV1) is also assessed. Estimated global DTP3 coverage has remained at 84%-86% since 2009, with estimated 2014 coverage at 86%. Estimated global coverage for the 2nd routine dose of measles-containing vaccine (MCV2) was 38% by age 24 months and 56% when older age groups were included, similar to levels reported in 2013 (36% and 55%, respectively). To reach and sustain high immunization coverage in all countries, adequate vaccine stock management and additional opportunities for immunization, such as through routine visits in the second year of life, are integral components to strengthening immunization programs and reducing morbidity and mortality from vaccine preventable diseases.
Vaccination coverage represents the percentage of persons in a target age group that received a vaccine dose. Administrative coverage is calculated by dividing the number of vaccine doses administered to those in a specified target age group by the estimated target population. Countries report administrative coverage annually to WHO and the United Nations Children's Fund (UNICEF) through the Joint Reporting Form (JRF).* Vaccine stock management information, including availability and supply, is also reported through the JRF. Vaccination coverage surveys estimate vaccination coverage by visiting a representative sample of households with children in a specified target age group to obtain information on vaccination status. WHO and UNICEF derive national coverage estimates through an annual country-by-country review of all available data, including administrative and survey-based coverage. As new data are incorporated, revisions of past coverage estimates (2, 3) and updates are published on the WHO and UNICEF websites (4, 5) . The WHO/UNICEF estimates of national immunization coverage, on which this report is based, are revised annually and include retrospective changes in estimates if new data become available.
In 2014, estimated DTP3 coverage was 86% worldwide among infants aged ≤12 months, ranging from 77% in the WHO African Region to 96% in the Western Pacific Region, and representing 115.2 million vaccinated children (Table 1) . Approximately 18.7 million eligible children did not complete the 3-dose series; among whom 11.5 million (61%) did not receive the 1st DTP dose, and 7.2 million (39%) started, but did not complete the 3-dose series. Estimated global coverage with BCG, polio3, and MCV1 was 91%, 86%, and 85%, respectively. During 2014, a total of 129 (66%) of 194 WHO countries achieved ≥90% national DTP3 coverage; and 57 (29%) achieved ≥80% DTP3 coverage in every district. National DTP3 coverage was 80%-89% in 30 countries, 70%-79% in 20 countries, and <70% in 15 countries. Among the 18. Additional vaccines are increasingly being introduced into national immunization schedules. By the end of 2014, hepatitis B vaccine was included in the routine immunization schedule in 184 (95%) countries, 96 (49%) of which included a dose administered within 24 hours of birth to prevent perinatal hepatitis B virus transmission. Worldwide (including countries that have not introduced the vaccine) coverage with 3 doses of hepatitis B vaccine in 2014 was 82%, and hepatitis B vaccine birth-dose coverage was 38% (Table 1) . Rubella vaccine has been introduced into the routine immunization schedule in 140 (72%) countries, with an estimated coverage of 46% globally. Coverage with 3 doses of Haemophilus influenzae type b vaccine, which had been introduced in 192 (99%) countries † by 2014, was 56%. By 2014, rotavirus vaccine had been introduced in 74 (38%) countries, and pneumococcal conjugate vaccine (PCV) in 117 (60%) countries. Coverage with the completed rotavirus vaccination series (2 or 3 doses, depending on the vaccine used) was 19% globally, and coverage with 3 doses of PCV was 31%. MCV2 was included in the practices, and careful communication and social mobilization efforts to inform caregivers of the need for additional vaccines beyond infancy. Countries that already have an established health intervention visit during the second year of life might be better poised to introduce or add vaccines because of the opportunity to synergize between programs while minimizing the burden on health care workers and systems (7) .
Strategies that promote vaccination beyond infancy can help create a safety net to improve coverage after service interruptions. Additionally, countries with established health care visits in the second year of life have an opportunity to work more broadly toward a life course vaccination strategy, whereby all persons are protected through routine immunization visits from infancy through adulthood, and important vaccine and health messages are reinforced at each visit. MSM have not previously been considered at increased risk for meningococcal disease. Determining outbreak thresholds* for special populations of unknown size (such as MSM) can be difficult. The New York City health department declared an outbreak based on an estimated increased risk for meningococcal infection in 2012 among MSM and human immunodeficiency virus (HIV)-infected MSM compared with city residents who were not MSM or for whom MSM status was unknown (1) . The Chicago Department of Public Health also declared an outbreak based on an increase in case counts and thresholds calculated using population estimates of MSM and HIV-infected MSM. Local public health response included increasing awareness among MSM, conducting contact tracing and providing chemoprophylaxis to close contacts, and offering vaccination to the population at risk (1-3). To better understand the epidemiology and burden of meningococcal disease in MSM populations in the United States and to inform recommendations, CDC analyzed data from a retrospective review of reported cases from January 2012 through June 2015.
In May 2013 and again in August 2015, CDC requested that health departments review all cases of probable or confirmed meningococcal disease caused by any serogroup and reported among males during January 2012-June 2015 to the National Notifiable Disease Surveillance System and, if possible, determine MSM status. The requests were made through Epi-X, a secure communications network for public health officials, and follow-up with each state health department occurred through individual e-mail correspondence. All 50 state health departments and the health departments of New York City, Los Angeles County, Chicago, and the District of Columbia responded to CDC's request for information. Analysis of the data was restricted to cases occurring among MSM aged 18-64 years.
During the case review period, 527 meningococcal disease cases among males aged 18-64 years were reported. Although MSM status is not routinely collected as part of national meningococcal case reporting and might be underreported, 74 cases were identified among MSM: 23 from New York City, 14 from Los Angeles County, 11 from Chicago, and 26 sporadic cases occurring in states or geographic areas where fewer than three cases of the same meningococcal serogroup were reported among MSM during a 3-month period (4) ( Table) . MSM status could not be verified for the other 453 meningococcal disease cases among men aged 18-64 years using available data, nor could CDC distinguish between health departments reporting zero cases in MSM and those that had no data on MSM status.
Among the 74 reported cases among MSM aged 18-64 years, the median age was 31 years (range = 20-59 years). Thirtyseven (52%) of 71 patients with known race were white, 29 (41%) were black, two (3%) were Asian, and three (4%) were other race. Neisseria meningitidis serogroup C accounted for 62 (84%) cases; serogroups B, W, and Y accounted for five, two, and three cases, respectively; and the serogroup for two patients was unknown. Overall, 24 (32%) cases were fatal, including six of the New York City cases (26%), five (36%) of the Los Angeles County cases, three (27%) of the Chicago cases, and 10 (38%) of the sporadic cases. Among 63 patients for whom HIV status was reported, 37 (59%) were HIV-positive; among these, 11 (30%) died. Meningococcal vaccination status was known for 41 patients; among these, six (15%) were vaccinated with a quadrivalent meningococcal vaccine. Five of the six vaccinated patients had serogroup C meningococcal disease, and two of the five died. Further analysis of meningococcal disease rates, risk factors, and pulsed-field gel electrophoresis data from all cases identified among MSM is ongoing.
Notes from the Field
* Occurrence of three or more confirmed or probable cases during a period of ≤3 months among persons who are not close contacts of each other and who do not share a common affiliation, with a primary attack rate of at least 10 cases per 100,000 population.
Information on MSM and HIV status of men reported with meningococcal disease is not currently noted on most meningococcal case report forms. However, representative and complete data on MSM and HIV status are needed to better understand the epidemiology of and potential risk factors for meningococcal disease among MSM in the United States and to inform prevention and control recommendations.
Health departments are encouraged to attempt to determine MSM and HIV status during investigations of meningococcal disease cases caused by any serogroup occurring among males aged ≥16 years. If permitted by state law, state health departments are asked to complete a supplemental case report form (available at http://www.cdc.gov/meningococcal/ surveillance/index.html) for all cases of meningococcal disease occurring among MSM and submit the forms to CDC via e-mail (meningnet@cdc.gov) or via fax (404-315-4681).
Get Smart About Antibiotics WeekNovember 16-22, 2015
Every year, more than 2 million persons in the United States are infected with antibiotic-resistant bacteria and approximately 23,000 persons die as a result of these infections (1) . The rise of antibiotic resistance continues to represent a serious threat to human and animal health, national security, and economies worldwide. November 16-22, 2015, is Get Smart About Antibiotics Week, an annual observance to raise awareness of the threat of antibiotic resistance and the importance of appropriate antibiotic prescribing and use.
The use of antibiotics is the single most important factor leading to antibiotic resistance around the world. Earlier this year, the White House released the National Action Plan to Combat Antibiotic-Resistant Bacteria, a roadmap to guide activities like stewardship programs. In addition, stakeholders joined a White House Forum on Antibiotic Stewardship to raise awareness and encourage partners to commit to focusing on stewardship activities in the coming years. The commitments made by those invested in this issue will set the course to help the nation make measurable progress on this important public health threat.
Get Smart About Antibiotics Week is a key component of CDC's efforts to improve antibiotic stewardship in communities, health care facilities, nursing homes, and on farms in collaboration with state-based programs and nonprofit and for-profit partners. Get Smart About Antibiotics Week coincides with the World Health Organization's first World Antibiotic Awareness Week and many other global antibiotic resistance observances, including those in Europe, Australia, and Canada. Information on scheduled activities and how to get involved in combating antibiotic resistance is available at http://www.cdc.gov/getsmart/week/index.html. US Department of Health and Human Services/Centers for Disease Control and Prevention * With 95% confidence interval. † Based on family member's responses to the question "During the past 12 months, was there any time when a person needed medical care, but did not get it because the person couldn't afford it?" and to a question asking if, during the past 12 months, the person delayed seeking or obtaining medical care because of worry about the cost. § Counties were classified into urbanization levels based on a classification scheme developed by NCHS that considers metropolitan/nonmetropolitan status, population, and other factors. ¶ Estimates are based on household interviews of a sample of the civilian, noninstitutionalized U.S. population, and are derived from the National Health Interview Survey family core questionnaire.
During 2012-2014, the percentage of adults aged 18-64 years who did not get or who delayed medical care during the last 12 months because of cost was higher in nonmetropolitan counties (14.6%) compared with metropolitan counties (10.6%-13.0%). Among adults residing in metropolitan counties, those in large fringe metropolitan counties were less likely to report not getting or delaying medical care (10.6%) compared to those in large central metropolitan counties (12.1%), medium metropolitan counties (12.6%), and small metropolitan counties (13.0%).
Sources: National Health Interview Survey. Available at http://www.cdc.gov/nchs/nhis.htm. NCHS urban-rural classification scheme for counties. Available at http://www.cdc.gov/nchs/data/series/sr_02/sr02_154.pdf. 
